Stockreport

Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

Affimed N.V.  (AFMD) 
Last affimed n.v. earnings: 11/19 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: affimed.com/investor-relations.php
PDF Best response data from 18 patients confirms favorable safety profile and overall response rate of 89% Management to host conference call today at 8:30 a.m. ET / 2: [Read more]